We are live on
!
Find out more
Ken Fisher Fisher Asset Management
AUM
$295B
1-Year Est. Return
32.61%
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
This Fund
S&P 500
1 Year Est. Return
+32.61%
AUM
$295B
AUM Growth
+$1.9B
(+0.65%)
Holding
1,133
Top Buys
| 1 | +$1.88B | |
| 2 | +$1.41B | |
| 3 | +$1.17B | |
| 4 |
Cisco
CSCO
|
+$1.1B |
| 5 |
Novartis
NVS
|
+$984M |
Top Sells
| 1 | +$1.74B | |
| 2 | +$1.21B | |
| 3 | +$1.06B | |
| 4 |
Stryker
SYK
|
+$955M |
| 5 |
Boston Scientific
BSX
|
+$695M |
Sector Composition
| 1 | Technology | 23.16% |
| 2 | Financials | 17.3% |
| 3 | Industrials | 10.45% |
| 4 | Healthcare | 9.91% |
| 5 | Energy | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
BridgeBio Pharma
BBIO
$13.3B
| $26.1M | 0.01% |
351,628
+119,227
|
|
||
302
BioCryst Pharmaceuticals
BCRX
$2.27B
| $26M | 0.01% |
2,733,253
+265,686
|
|
||
303
Ligand Pharmaceuticals
LGND
$5.08B
| $25.6M | 0.01% |
127,994
-2,864
|
|
||
304
Nutanix
NTNX
$13.4B
| $25.5M | 0.01% |
669,961
-12,658
|
|
||
305
AAR Corp
AIR
$5.22B
| $25.2M | 0.01% |
230,570
+23,567
|
|
||
306
Del Monte Corporation
FDP
$1.37B
| $25.2M | 0.01% |
626,200
+31,932
|
|
||
307
Snap-on
SNA
$20B
| $25.1M | 0.01% |
69,046
+3,029
|
|
||
308
Texas Capital Bancshares
TCBI
$4.4B
| $24.4M | 0.01% |
257,394
-33,962
|
|
||
309
RLJ Lodging Trust
RLJ
$1.68B
| $24.4M | 0.01% |
3,285,234
+157,822
|
|
||
310
Capri Holdings
CPRI
$2.43B
| $24.2M | 0.01% |
1,373,601
-155,339
|
|
||
311
First Trust Dow Jones Internet Index Fund ETF
FDN
$5.17B
| $24.1M | 0.01% |
103,182
-3,947
|
|
||
312
SiteOne Landscape Supply
SITE
$4.75B
| $24.1M | 0.01% |
180,694
+9,167
|
|
||
313
Veracyte
VCYT
$4.06B
| $23.7M | 0.01% |
736,270
-59,442
|
|
||
314
Astronics
ATRO
$3.26B
| $23.3M | 0.01% |
348,842
+288,201
|
|
||
315
F5
FFIV
$22.4B
| $23.1M | 0.01% |
79,719
-288
|
|
||
316
V2X
VVX
$2.74B
| $22.9M | 0.01% |
334,316
+134,300
|
|
||
317
Worthington Enterprises
WOR
$2.95B
| $22.6M | 0.01% |
433,588
-3,143
|
|
||
318
Scholar Rock
SRRK
$5.5B
| $22.5M | 0.01% |
458,017
-73,422
|
|
||
319
First American
FAF
$6.76B
| $22.4M | 0.01% |
371,430
-20,846
|
|
||
320
ProPetro Holding
PUMP
$1.86B
| $21.5M | 0.01% |
1,494,983
-693
|
|
||
321
RenaissanceRe
RNR
$12.8B
| $21.2M | 0.01% |
71,470
-1,499
|
|
||
322
Steel Dynamics
STLD
$39.3B
| $21.1M | 0.01% |
117,383
+12,300
|
|
||
323
Revolution Medicines
RVMD
$34B
| $21M | 0.01% |
215,947
-25,110
|
|
||
324
Fluor
FLR
$7.05B
| $21M | 0.01% |
449,425
-13,737
|
|
||
325
State Street Health Care Select Sector SPDR ETF
XLV
$39B
| $20.9M | 0.01% |
142,880
+12,938
|
|